Sažetak
Uvod. Botulizam predstavlja neurointoksikaciju izazivanu toksinom koji luči Clostridium botulinum. Zbog visoke toksičnosti i smrtnosti, ovaj otrov se može koristiti kao biološko oružje. Prikaz bolesnika. Prikazano je šest bolesnika, srednje starosti 28,8 godina, koji su konzumirali konzervisanu hranu i kod kojih je dijagnoza postavljena na osnovu tipične kliničke slike. Najčešći simptomi, prisutni kod svih bolesnika bili su: zamagljen vid, dupla slika (diplopija), suva usta i opstipacija. Najduže lečenje primenjeno je kod bolesnika kod kojeg je bolest prepoznata tek posle 23 dana i koji nije primio serum antibotulinum. Svi bolesnici su primili antibiotike, a četvoro je primilo antitoksin. Neostigmin i klistir su korišćeni za lečenje poremećaja pokretljivosti creva i opstipacije. Zaključak. Dijagnoza botulizma bila je postavljena se na osnovu afebrilnosti, očuvanog stanja svesti, duple slike, suvih usta i podataka o konzumiranju sumnjive hrane. Polivalentni antibotulinski serum treba da se primeni što pre, jer smanjuje pojavu komplikacija, dužinu bolničkog lečenja i stopu smrtnosti.
Ključne reči
Array
Array
Array
Array
Array
Array
Array
Array
Array
Array
Array
Reference
Simpson LL. Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol 2004; 44: 167−93.
Konstantinović L, Krstic M, Kostic V, Rankovic J, Jovanovic M, Vrbić M. Clinical infectious diseases. Nis: University of Nis, 2001.(Serbian)
Eriksen T, Brantsaeter AB, Kiehl W, Steffens I. Botulism infection after eating fish in Norway and Germany: two outbreak re-ports. Euro Surveill 2004; 8(3): pii=2366.
Mayo Clinic Staff. Botulism treatments and drugs. Available from: http://www.mayoclinic.org/diseases-conditions/botulism/basics/treatment/con-20025875 [last ac-cesed 2015 September 1].
Rummel A, Eichner T, Weil T, Karnath T, Gutcaits A, Mahrhold S, et al. Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept. Proc Natl Acad Sci U S A 2007; 104(1): 359−64.
Dong M, Tepp WH, Liu H, Johnson, EA, Chapman ER. Mecha-nism of botulinum neurotoxin B and G entry into hippocam-pal neurons. J Cell Biol 2007; 179(7): 1511−22.
Christopher GW, Cieslak TJ, Pavlin JA, Eitzen EM Jr. Biological warfare. A historical perspective. JAMA 1997; 278(5): 412−7.
Ongrade J. Microbial warfare and bioterrorism Orv Hetil 2002; 143(33): 1935−9. (Hungarian)
Dembek ZF, Smith LA, Rusnak JM. Botulism: cause, effects, di-agnosis, clinical and laboratory identification, and treatment modalities. Disaster Med Public Health Prep 2007; 1(2): 122−34.
Rotz LD, Khan AS, Lillibridge SR, Ostroff SM, Hughes JM. Public health assessment of potential biological terrorism agents. Emerg Infect Dis 2002; 8(2): 225−30.
Centers for Disease Control and Prevention (CDC). Botulism. General information. Atlanta, Georgia: US Department of Health and Human Services, CDC; 2014.
Sobel J, Tucker N, Sulka A, McLaughlin J, Maslanka S. Foodborne botulism in the United States, 1990-2000. Emerg Infect Dis 2004; 10(9): 1606−11.
Leclair D, Fung J, Isaac-Renton JL, Proulx JF, May-Hadford J, Ellis A, et al. Foodborne botulism in Canada, 1985-2005. Emerg Infect Dis 2013; 19 (6): 961−8.
Bouvet P, Ruimy R, Bouchier C, Faucher N, Mazuet C, Popoff MR. An atypical Clostridium strain related to the Clostridium botu-linum group III strain isolated from a human blood culture. J Clin Microbiol 2014; 52(1): 339−43.
Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, et al. Botulinum toxin as a biological weapon: med-ical and public-health management. JAMA 2001; 285(8): 1059−70.
Marcus N, Hourvitz A. Botulism disease. Harefuah 2002; 141(Spec No): 73−7, 120. (Hebrew)
Gutzwiller FS, Steffen R, Mathys P, Walser S, Schmid H, Mütsch M. Botulism: prevention, clinical diagnostics, therapy and possible threat. Dtsch Med Wochenschr 2008; 133(16): 840−5. (Ger-man)
Arora A, Sharma CM, Kumawat B, Khandelwal D. Rare presenta-tion of botulism with generalized fasciculations. Int J Appl Basic Med Res 2014; 4(1): 56−8.
Angulo FJ, Getz J, Taylor JP, Hendricks KA, Hatheway CL, Barth SS et al. A Large Outbreak of Botulism: The Hazardous Baked Potato. J Infect Dis 1998; 178(1): 172–7.
Sobel J. Botulism. Clin Infect Dis 2005; 41(8): 1167−73.
Khakshoor H, Moghaddam AS, Vejdani AH, Armstrong BK, Moshirfar M. Diplopia as the primary presentation of food-borne botulism. Oman J Ophthalmol 2012; 5(2): 109−11.
Vossen MG, Gattringer KB, Wenisch J, Khalifeh N, Koreny M, Spertini V, et al. The First Case(s) of Botulism in Vienna in 21 Years: A Case Report. Case Rep Infect Dis 2012; 2012: 438989.
Kotan D, Aygul R, Ceylan M, Yilikoglu Y. Clinically and electro-physiologically diagnosed botulinum intoxication. BMJ Case Rep 2013; 2013: pii: bcr0120125678.
Goonetilleke A, Harris JB. Clostridial neurotoxins. Neurol Neu-rosurg Psychiatry 2004; 75(Suppl 3): iii35−9.
Lonati D, Locatelli CA, Fenicia L, Anniballi F, Landri P, Giampreti A, et al. Fatal course of foodborne botulism in an eight-month old infant. Pediatr Rep 2011; 3(4): e31.
Lonati D, Locatelli CA, Fenicia L, Anniballi F, Landri P, Giampreti A, et al. Treatment of foodborne botulism in current clinical toxicology: authors' reply. Pediatr Rep 2012; 4(3): e27.
Robinson RF, Nahata MC. Management of botulism. Ann Pharmacother 2003; 37(1): 127−31.
Tacket CO, Shandera WX, Mann JM, Hargrett NT, Blake PA. Eq-uine antitoxin use and other factors that predict outcome in type A foodborne botulism. Am J Med 1984; 76(5): 794−8.
Thanongsaksrikul J, Chaicumpa W. Botulinum neurotoxins and botulism: a novel therapeutic approach. Toxins (Basel) 2011; 3(5): 469−88.
Momose Y, Asakura H, Kitamura M, Okada Y, Ueda Y, Hanabara Y, et al. Food-borne botulism in Japan in March 2012. Int J Infect Dis 2014; 24: 20−2.
Black RE, Gunn RA. Hypersensitivity reactions associated with botulinal antitoxin. Am J Med 1980; 69(4): 567−70.